Organizational Chart International Technology Transfer General Information Career Opportunities


Spacer

 
Licensing & Royalties
spacer
 

Licensing Opportunities

Technology Abstracts

Print This Abstract Apply Questions ?
Methods and Compositions for Transforming Dendritic Cells and Activating T Cells

Description of Invention:
T cells mediate most forms of cellular immunity. Typically T cells do not respond to free antigenic peptides, but instead T cells interact with a specialized set of cell surface proteins, which are the class I and class II major histocompatibility complexes, or MHC. Specialized antigen-presenting cells, such as macrophage and dendritic cells, present antigenic peptides on the surface cells in conjunction with the MHC molecules, and induce cytotoxic T cells to proliferate. T cells are induced by these antigen-presenting cells to recognize corresponding antigens expressed on MHC antigens on the surface of target cells, and destroy these target cells.

This invention describes a novel method for making transformed dendritic cells with any recombinant nucleic acid, which have been difficult to transduce using existing methods. Recombinant dendritic cells are made by transforming a stem cell and differentiating the stem cell into a dendritic cell. The resulting dendritic cell is an antigen-presenting cell that activates T cells against MHC class I-antigen targets. The present invention provides a valuable tool for the treatment of cancer, and viral and parasitic infections using the recombinant dendritic cells. The invention also provides therapeutic compositions and pharmaceutical compositions.



Inventors:
Patrick Hwu et al. (NCI)

Patent Status:
DHHS Reference No. E-040-1996/0-US-07 (U.S. Patent No. 6,734,014 issued 11 May 2004)

Relevant Publication: This research is described in Reeves et al., “Retroviral Transduction of Human Dendritic Cells with a Tumor-Associated Antigen Gene,” Cancer Res. 1996 Dec15, 56(24):5672-5677.


Portfolios:
Gene Based Therapies
Cancer

Cancer -Therapeutics-Biological Response Modifiers-Cytokines
Gene Based Therapies -Therapeutics-Gene Therapy-Delivery Systems
Cancer -Therapeutics
Gene Based Therapies -Therapeutics

For Additional Information Please Contact:
Michelle A. Booden Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)451-7337
Email: boodenm@mail.nih.gov
Fax: (301) 402-0220


Web Ref: 414

Updated: 8/04

 

 
 
Spacer